Key presentations at the 2013 San Antonio Breast Cancer Symposium (SABCS; December 10–14, 2013) addressed the role of bisphosphonates in early-stage breast cancer, bevacizumab in HER2-positive disease, and local therapy for metastatic disease. These findings are summarized below. For more information about the symposium, please visit the SABCS website.
Bisphosphonates with Adjuvant Therapy for Early-Stage Breast Cancer
Survival was improved and bone metastases were reduced in postmenopausal women.
The role of bisphosphonates as a component of adjuvant therapy in early-stage breast cancer to reduce recurrences has been debated for several years. Conflicting data sets have resulted in recommendations to avoid incorporating bone agents as a stand…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)